Another prognostic biomarker, GAS6-AS1, is a potential target for therapeutic approaches in hepatocellular carcinoma (HCC), where knock-down of GAS6-AS1 decreased tumor growth in vivo (Ai et al., 2020). Here, GAS6 is linked to neoplasm.